Table 3.
Consensus on pharmacological strategy for maintenance treatment
| Bipolar I | Bipolar II | Rapid cycling | |
|---|---|---|---|
| Li + AAP | 1st | 2nd | 2nd |
| Li only | Treatment of choice | 1st | 2nd |
| VAP + AAP | No consensus | 2nd | 2nd |
| VAP only | 2nd | No consensus | 2nd |
| LTG + AAP | 2nd | 2nd | 2nd |
| LTG only | 2nd | 2nd | No consensus |
| CBZ only | 3rd | 2nd | 2nd |
| OLZ only | 2nd | 2nd | 2nd |
| ARP only | No consensus | 2nd | No consensus |
| QTP only | 2nd | 2nd | 2nd |
| RIS only | 3rd | 3rd | 2nd |
| ASP only | 3rd | 3rd | 3rd |
| Li + VAP | 2nd | 2nd | 2nd |
| Li + LTG | 2nd | 2nd | 2nd |
| VAP + LTG | No consensus | No consensus | No consensus |
| Li + AD | 2nd | No consensus | 3rd |
| VAP + AD | 3rd | 3rd | 3rd |
| LTG + AD | 3rd | 3rd | 3rd |
| AD only | 3rd. | 3rd | 3rd |
| MS + TH | 3rd | 3rd | 3rd |
Abbreviations: AD, antidepressant; AAP, atypical antipsychotic; ARP, aripiprazole; ASP, asenapine; CBZ, carbamazepine; CI, confidence interval; Li, lithium; LTG, lamotrigine; MS, mood stabilizer; OLZ, olanzapine; QTP, quetiapine; RIS, risperidone; SD, standard deviation; TH, thyroid hormone; VAP, valproic acid.